FDA approves new type of schizophrenia drug
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release.
“This drug takes the first new approach to schizophrenia treatment in decades,” said Tiffany Farchione, the director of the Division of Psychiatry, Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research. “This approval offers a new alternative to the antipsychotic medications people with schizophrenia have previously been prescribed.”
The drug, Cobenfy, is the first anti-psychotic drug approved to treat schizophrenia that targets a different receptor than what has typically been the standard of care, the release said.
“Schizophrenia is a leading cause of disability worldwide. It is a severe, chronic mental illness that is often damaging to a person’s quality of life,” Farchione added.
According to the press release, about 1 percent of Americans have schizophrenia and the condition is one of the 15 leading causes of disability. People with the illness are at greater risk of dying at a younger age and nearly 5 percent of deaths are linked to suicide, the release said.
The approval was granted by the Bristol-Myers Squibb Company.
The first medicine that's been proven to reduce deaths among people infected with coronavirus is expected to save thousands of ENGAGE+
By Cara Murez HealthDay ReporterMONDAY, Feb. 8, 2021 (HealthDay News) -- While scientists still don't know what causes Parkinson's disease, ENGAGE+
For their trial, Al-Hendy and his colleagues recruited 770 women from several countries, including the United States. All had heavy ENGAGE+
The Moderna and Pfizer vaccines were tested before the discovery of variants from the United Kingdom, South Africa, and Brazil, ENGAGE+
Dr. J. Michael Bostwick, Professor of psychiatry at Mayo Clinic in Rochester, MN, discusses his article appearing in the February ENGAGE+
US regulators say Johnson and Johnson's single-shot vaccine is safe, and could be approved in days. Source link
Speaking on television, French Health Minister Olivier Véran said people with pre-existing conditions - such as high blood pressure or ENGAGE+
WEDNESDAY, March 3, 2021 (HealthDay News) -- A new study provides further evidence that people with certain blood types may ENGAGE+